4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Monica M. Mahathre, Padmashree C. G. Rida, Ritu Aneja. The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers[J]. The Journal of Biomedical Research, 2016, 30(6): 441-451. DOI: 10.7555/JBR.30.20150109
Citation: Monica M. Mahathre, Padmashree C. G. Rida, Ritu Aneja. The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers[J]. The Journal of Biomedical Research, 2016, 30(6): 441-451. DOI: 10.7555/JBR.30.20150109

The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers

More Information
  • Received Date: August 07, 2015
  • Colon cancer is currently the third most common cancer and second most fatal cancer in the United States, resulting in approximately 600,000 deaths annually. Though colorectal cancer death rates are decreasing by about 3% every year, disease outcomes could be substantially improved with more research into the drivers of colon carcinogenesis, the determinants of aggressiveness in colorectal cancer and the identification of biomarkers that could enable choice of more optimal treatments. Colon carcinogenesis is notably a slow process that can take decades. Known factors that contribute to the development of colon cancer are mutational, epigenetic and environmental, and risk factors include age, history of polyps and family history of colon cancer. Colorectal cancers exhibit heterogeneity in their features and are often characterized by the presence of chromosomal instability, microscopic satellite instability, or CpG island methylator phenotype. In this review, we propose that centrosome amplification may be a widespread occurrence in colorectal cancers and could potently influence tumor biology. Moreover, the quantitation of this cancer-specific anomaly could offer valuable prognostic information and pave the way for further customization of treatment based on the organellar profile of patients. Patient stratification models that take into account centrosomal status could thus potentially reduce adverse side effects and result in improved outcomes for colorectal cancer patients.
  • Related Articles

    [1]Fanyu Peng, Yizhi Ge, Rongrong Wang, Dingdong Hu, Xiang Cao, Yujie Zhang, Dan Zong, Xia He. Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study[J]. The Journal of Biomedical Research, 2022, 36(4): 221-230. DOI: 10.7555/JBR.36.20220060
    [2]Sun Zhen, Liu Chen, Cheng Steven Y.. Identification of four novel prognosis biomarkers and potential therapeutic drugs for human colorectal cancer by bioinformatics analysis[J]. The Journal of Biomedical Research, 2021, 35(1): 21-35. DOI: 10.7555/JBR.34.20200021
    [3]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [4]Timothy McAlindon, Eckart Bartnik, Janina S. Ried, Lenore Teichert, Matthias Herrmann, Klaus Flechsenhar. Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited[J]. The Journal of Biomedical Research, 2017, 31(1): 25-30. DOI: 10.7555/JBR.31.20150167
    [5]Jianming Wu, Ling Li. Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications[J]. The Journal of Biomedical Research, 2016, 30(5): 361-372. DOI: 10.7555/JBR.30.20150131
    [6]Tinghua Hu, Yu Yao, Shuo Yu, Hui Guo, Lili Han, Wenjuan Wang, Tao Tian, Yibin Hao, Zhiyan Liu, Kejun Nan, Shuhong Wang. Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer[J]. The Journal of Biomedical Research, 2013, 27(4): 283-290. DOI: 10.7555/JBR.27.20130069
    [7]Songyu Cao, Cheng Wang, Xinen Huang, Juncheng Dai, Lingmin Hu, Yao Liu, Jiaping Chen, Hongxia Ma, Guangfu Jin, Zhibin Hu, Lin Xu, Hongbing Shen. Prognostic assessment of apoptotic gene polymorphisms in non-small cell lung cancer in Chinese[J]. The Journal of Biomedical Research, 2013, 27(3): 231-238. DOI: 10.7555/JBR.27.20130014
    [8]Wenze Sun, Liping Song, Ting Ai, Yingbing Zhang, Ying Gao, Jie Cui. Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer[J]. The Journal of Biomedical Research, 2013, 27(3): 220-230. DOI: 10.7555/JBR.27.20130004
    [9]Lihong Chen, Lianxiang Li, Feng Chen, Dalin He. Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma[J]. The Journal of Biomedical Research, 2012, 26(4): 274-277. DOI: 10.7555/JBR.26.20110103
    [10]Shuangshuang Wang, Ping Zhao, Brian Cao. Development and optimization of an antibody array method for potential cancer biomarker detection[J]. The Journal of Biomedical Research, 2011, 25(1): 63-70. DOI: 10.1016/S1674-8301(11)60008-0
  • Cited by

    Periodical cited type(6)

    1. Bühler M, Fahrländer J, Sauter A, et al. GPER1 links estrogens to centrosome amplification and chromosomal instability in human colon cells. Life Sci Alliance, 2022, 6(1): e202201499. DOI:10.26508/lsa.202201499. Print 2023 Jan
    2. Bühler M, Stolz A. Estrogens-Origin of Centrosome Defects in Human Cancer?. Cells, 2022, 11(3): 432. DOI:10.3390/cells11030432
    3. Kalkan BM, Ozcan SC, Quintyne NJ, et al. Keep Calm and Carry on with Extra Centrosomes. Cancers (Basel), 2022, 14(2): 442. DOI:10.3390/cancers14020442
    4. Jia ZH, Wang XG, Zhang H. Overcome cancer drug resistance by targeting epigenetic modifications of centrosome. Cancer Drug Resist, 2019, 2(2): 210-224. DOI:10.20517/cdr.2018.010
    5. Li JA, Liu BC, Song Y, et al. Cyclin A2 regulates symmetrical mitotic spindle formation and centrosome amplification in human colon cancer cells. Am J Transl Res, 2018, 10(8): 2669-2676.
    6. Harrison LE, Bleiler M, Giardina C. A look into centrosome abnormalities in colon cancer cells, how they arise and how they might be targeted therapeutically. Biochem Pharmacol, 2018, 147: 1-8. DOI:10.1016/j.bcp.2017.11.003

    Other cited types(0)

Catalog

    Article Metrics

    Article views (3308) PDF downloads (506) Cited by(6)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return